

Neu-QAP

(an EXTERNAL QUALITY ASSURANCE PROGRAMME)



PARTICIPANT FINAL ASSESSMENT REPORT

PT SCHEME:SEROLOGY

Cycle No	C5
Ref.No.	NEUQAP610
Sample ID	NEUQAP SERO SERUM/2023/10/C5/S3

Report Date: 28/12/2023

Sample: October 2023

Peer group

Parameters	Lab Report	No of Participants	Consensus Report	%	Remarks
HBsAg (Card Method)	Reactive	15	Non Reactive - 1 Reactive - 14	93	Within Consensus
HCV (Card method)	Equivocal	16	Non Reactive - 4 Reactive - 11 Equivocal - 1		Out of Consensus
HIV-1 & 2 (Card method)	Reactive	14	Non Reactive - 1 Reactive - 13	93	Within Consensus
RPR (Others)	Non Reactive	4	Non Reactive - 3 Reactive - 1	75	Within Consensus
Widal (Slide agglutination)	Negative	25	Negative - 25	100	Within Consensus

Authorised Signatory

Dr. Sujay Prasad

Technical Manager and Program coordinator

This report is for use only by the intended participant.

Technical Advisor

Dr Divya Page 2 of 4



CLUEPATH DIAGNOSTICS



INVESTIGATION FORM FOR PT / EQAS OUTLIERS

Date: 31st December 2023

Proficiency test provider: NeuQAP October 2023 Cycle 1.

2. Proficiency test analyte: Anti HCV (Rapid)

- Details of outlier / failure: result was graded as 'out of consensus'. The lab had reported the result as 'equivocal' against expected result of 'Reactive'
- Investigation done, Root cause analysis and action taken:
 - a) Verified the data updated for transcriptional errors and found that the result was updated as 'equivocal' even though the result was 'reactive' by an error while selecting from the drop box.
 - b) The image of the card uploaded was examined and found that the result was indeed 'Reactive'.
 - c) The technicians were oriented and trained towards entering the results into website with due diligence and an additional review is implemented for the transcription going forward.
- 5. Signatures:

Lab manager / Sr. Technician: Salahwulli

Laboratory Director: